Cancer gene therapy - Cell Genesys/LICR

Drug Profile

Cancer gene therapy - Cell Genesys/LICR

Alternative Names: Angiogenesis inhibibitor gene therapy

Latest Information Update: 16 Oct 2006

Price : $50

At a glance

  • Originator Ludwig Institute for Cancer Research
  • Class Antineoplastics; Gene therapies
  • Mechanism of Action Vascular endothelial growth factor receptor 3 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 16 Oct 2006 Discontinued for Cancer in USA (unspecified route)
  • 15 Aug 2003 unspecified for Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top